Drug Information

Drug General Information
Drug ID
D07YHM
Former ID
DIB003109
Drug Name
LY-2456302
Synonyms
Opioid receptor kappa (KOR) antagonist (alcohol dependence), Eli Lilly
Drug Type
Small molecular drug
Indication Alcohol use disorders [ICD9: 303; ICD10:F10.2] Phase 1 [524877]
Company
Eli Lilly & Co
Formula
C26H27FN2O2
Canonical SMILES
CC1=CC(=CC(=C1)C2CCCN2CC3=CC=C(C=C3)OC4=C(C=C(C=C4)C(=O<br />)N)F)C
InChI
1S/C26H27FN2O2/c1-17-12-18(2)14-21(13-17)24-4-3-11-29(24)16-19-5-8-22(9-6-19)31-25-10-7-20(26(28)30)15-23(25)27/h5-10,12-15,24H,3-4,11,16H2,1-2H3,(H2,28,30)/t24-/m0/s1
InChIKey
ZHPMYDSXGRRERG-DEOSSOPVSA-N
PubChem Compound ID
44129648
PubChem Substance ID
84982178, 89927679, 136928384, 136962195, 140729106, 164045062, 172650774, 198979705, 228730722, 242060151, 244435635
Target and Pathway
Target(s) Kappa-type opioid receptor Target Info Antagonist [532492]
KEGG Pathway Neuroactive ligand-receptor interaction
PANTHER Pathway Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway
Opioid prodynorphin pathway
Reactome Peptide ligand-binding receptors
G alpha (i) signalling events
WikiPathways GPCRs, Class A Rhodopsin-like
Peptide GPCRs
GPCR ligand binding
GPCR downstream signaling
References
Ref 524877ClinicalTrials.gov (NCT02218775) FASTMAS (New Experimental Medicine Studies: Fast-Fail Trials in Mood and Anxiety Spectrum Disorders) Kappa Opioid Receptor (KOR) Phase 1 Study. U.S. National Institutes of Health.
Ref 532492LY2456302 is a novel, potent, orally-bioavailable small molecule kappa-selective antagonist with activity in animal models predictive of efficacy in mood and addictive disorders. Neuropharmacology. 2014 Feb;77:131-44.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Tang and Dr. Zhang.